Author/Editor		Bon, Jurij; Barbič-Žagar, Breda; Bevec, Matevž
Title		Neintervencijsko spremljanje učinkovitosti in varnosti olanzapina (Zolrix) v zdravljenju shizofrenije in bipolarne manije
Translated title		Post-authorization safety and efficacy study of olanzapine (Zolrix) in the treatment of shizophrenia and bipolar mania
Type		članek
Source		Med Razgl
Vol. and No.		Letnik 50, št. 1
Publication year		2011
Volume		str. 97-9
Language		slo
Abstract		Schizophrenia and bipolar disorder are mental disorders that pose a real problem to the public health care system. Early diagnosis and treatment is instrumental in a relatively good management and control of these two diseeses. Second-generation antipsychotics increase the likelihood of selecting the right, optimal medicine, which enablcs effeceive treatment at reduced strength and frequency of adverse reactions. We conducted a post authorisation study in which 163 patients with schizophrenia and bipolar mania received olanzapine in the form of regular and orodispersible tablets (Zolrix / Zolrix orodispersible tablets, Krka, d. d., Novo mesto). Treatment with an average dose of 12.7 mg of olanzapine reduccd symptom expression in 79% of patients. Dueto improvement in symptoms 41%, of patients became only marginally ill or even symptom-free Olanzapine was very well tolerated by patients. Only in 25% of patients medicine-related adverse reactions were noted during monitoring, while at the end of monitoring the number feel to 17.8%. The post-authorisation study showed that the most frequent adverse reaction was weight gain, which was present in only 11% of patients treated with olanzapine.
Descriptors		SCHIZOPHRENIA BIPOLAR DISORDER ANTIPSYCHOTIC AGENTS